Shibayama T, Ohnoshi T, Ueoka H, Horiguchi T, Kodani T, Segawa Y, Maeda T, Miyatake K, Takigawa N, Kimura I
Second Department of Medicine, Okayama University Medical School, Japan.
Nihon Kyobu Shikkan Gakkai Zasshi. 1992 Jun;30(6):1097-102.
Serum NSE levels were measured in 126 patients with previously untreated NSCLC. The NSE level was greater than 10 ng/ml in 29 patients (23.0%) and this was considered to be positive. Elevation of serum NSE levels correlated closely with clinical stage except stage I and II. The effect of chemotherapy was evaluated in 74 cases included 22 NSE-positive cases. The response rate was 50% in positive cases and 34.6% in negative cases. However, the median duration of response in positive cases (2.2 months) was significantly shorter than that in negative cases (6.6 months). The median survival time of 6.0 months in positive cases was brief compared with 9.6 months in negative cases. These results indicate that elevation of serum NSE level in patients with NSCLC may be a marker of poor prognosis.
对126例未经治疗的非小细胞肺癌患者测定了血清神经元特异性烯醇化酶（NSE）水平。29例患者（23.0%）的NSE水平高于10 ng/ml，这被认为是阳性。血清NSE水平升高与除I期和II期外的临床分期密切相关。对74例患者进行了化疗效果评估，其中包括22例NSE阳性患者。阳性病例的缓解率为50%，阴性病例为34.6%。然而，阳性病例的中位缓解持续时间（2.2个月）明显短于阴性病例（6.6个月）。阳性病例的中位生存时间为6.0个月，明显短于阴性病例的9.6个月。这些结果表明，非小细胞肺癌患者血清NSE水平升高可能是预后不良的一个标志物。
